Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout

2025-08-13 23:58:40 ET

It has been a few months since my last Rigel Pharmaceuticals ( RIGL ) article , where I was bullish about their strong momentum coming out of Q1 with a 68% year-over-year revenue jump, as TAVALISSE, GAVRETO, and REZLIDHIA showing prospects for sustained growth. The company posted $11.4M Q1 net income with improvements in margins and solid operating leverage that should reduce the need for dilution. In addition, I was encouraged by R289’s progress and TAVALISSE’s patent extension to 2032. As a result, I was looking to add to RIGL around $17.50 per share. Now, RIGL is trading up roughly 65% since that article, following their record Q2 earnings with a huge beat on EPS and revenue as they continue to make significant progress both in the clinic and commercially. The company’s performance looks to have pushed RIGL to a potential breakout above $30 per share as investors realize Rigel is fully fueled for years of growth. As a result, I am adjusting my outlook and strategy for RIGL as we move deeper into the second half of 2025....

Read the full article on Seeking Alpha

For further details see: